Endothelin converting enzyme-1 expression in endometrial adenocarcinomas

Banu Arun, Gokhan Kilic, Raheela Ashfaq, Hossein M. Saboorian, Tunc Gokaslan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Endothelin-1 (ET-1) is a potent mitogen in various precursor tumor cells, including endometrial adenocarcinoma. It is proposed that ET-1 produced by endometrial adenocarcinoma may participate in the angiogenesis of this carcinoma in vivo. Endothelin converting enzyme-1 (ECE-1) is the key enzyme that synthesizes ET-1. In this study, we tried to demonstrate the expression of ECE-1 in endometrial carcinomas. Deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of ECE-1. Our study showed that the expression of ECE-1 was markedly increased in 9 of 15 (60%) well-differentiated endometrial adenocarcinomas; in contrast, only 2 out of 10 (20%) control specimens showed a mild labeling. With new selective inhibitory molecules emerging, research is currently evaluating the possible inhibition of ECE-1 as an alternative approach for the treatment of endometrial as well as other carcinomas.

Original languageEnglish (US)
Pages (from-to)779-782
Number of pages4
JournalCancer Investigation
Volume19
Issue number8
DOIs
StatePublished - 2001

Fingerprint

Adenocarcinoma
Endothelin-1
Carcinoma
Endometrial Neoplasms
Mitogens
Immunohistochemistry
Endothelin-Converting Enzymes
Enzymes
Research
Neoplasms
Therapeutics

Keywords

  • Endometrial cancer
  • Endothelin converting enzyme-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. / Arun, Banu; Kilic, Gokhan; Ashfaq, Raheela; Saboorian, Hossein M.; Gokaslan, Tunc.

In: Cancer Investigation, Vol. 19, No. 8, 2001, p. 779-782.

Research output: Contribution to journalArticle

Arun, Banu ; Kilic, Gokhan ; Ashfaq, Raheela ; Saboorian, Hossein M. ; Gokaslan, Tunc. / Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. In: Cancer Investigation. 2001 ; Vol. 19, No. 8. pp. 779-782.
@article{3e617e16008a4c829a675ec3fbe565bd,
title = "Endothelin converting enzyme-1 expression in endometrial adenocarcinomas",
abstract = "Endothelin-1 (ET-1) is a potent mitogen in various precursor tumor cells, including endometrial adenocarcinoma. It is proposed that ET-1 produced by endometrial adenocarcinoma may participate in the angiogenesis of this carcinoma in vivo. Endothelin converting enzyme-1 (ECE-1) is the key enzyme that synthesizes ET-1. In this study, we tried to demonstrate the expression of ECE-1 in endometrial carcinomas. Deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of ECE-1. Our study showed that the expression of ECE-1 was markedly increased in 9 of 15 (60{\%}) well-differentiated endometrial adenocarcinomas; in contrast, only 2 out of 10 (20{\%}) control specimens showed a mild labeling. With new selective inhibitory molecules emerging, research is currently evaluating the possible inhibition of ECE-1 as an alternative approach for the treatment of endometrial as well as other carcinomas.",
keywords = "Endometrial cancer, Endothelin converting enzyme-1",
author = "Banu Arun and Gokhan Kilic and Raheela Ashfaq and Saboorian, {Hossein M.} and Tunc Gokaslan",
year = "2001",
doi = "10.1081/CNV-100107738",
language = "English (US)",
volume = "19",
pages = "779--782",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Endothelin converting enzyme-1 expression in endometrial adenocarcinomas

AU - Arun, Banu

AU - Kilic, Gokhan

AU - Ashfaq, Raheela

AU - Saboorian, Hossein M.

AU - Gokaslan, Tunc

PY - 2001

Y1 - 2001

N2 - Endothelin-1 (ET-1) is a potent mitogen in various precursor tumor cells, including endometrial adenocarcinoma. It is proposed that ET-1 produced by endometrial adenocarcinoma may participate in the angiogenesis of this carcinoma in vivo. Endothelin converting enzyme-1 (ECE-1) is the key enzyme that synthesizes ET-1. In this study, we tried to demonstrate the expression of ECE-1 in endometrial carcinomas. Deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of ECE-1. Our study showed that the expression of ECE-1 was markedly increased in 9 of 15 (60%) well-differentiated endometrial adenocarcinomas; in contrast, only 2 out of 10 (20%) control specimens showed a mild labeling. With new selective inhibitory molecules emerging, research is currently evaluating the possible inhibition of ECE-1 as an alternative approach for the treatment of endometrial as well as other carcinomas.

AB - Endothelin-1 (ET-1) is a potent mitogen in various precursor tumor cells, including endometrial adenocarcinoma. It is proposed that ET-1 produced by endometrial adenocarcinoma may participate in the angiogenesis of this carcinoma in vivo. Endothelin converting enzyme-1 (ECE-1) is the key enzyme that synthesizes ET-1. In this study, we tried to demonstrate the expression of ECE-1 in endometrial carcinomas. Deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of ECE-1. Our study showed that the expression of ECE-1 was markedly increased in 9 of 15 (60%) well-differentiated endometrial adenocarcinomas; in contrast, only 2 out of 10 (20%) control specimens showed a mild labeling. With new selective inhibitory molecules emerging, research is currently evaluating the possible inhibition of ECE-1 as an alternative approach for the treatment of endometrial as well as other carcinomas.

KW - Endometrial cancer

KW - Endothelin converting enzyme-1

UR - http://www.scopus.com/inward/record.url?scp=0035216116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035216116&partnerID=8YFLogxK

U2 - 10.1081/CNV-100107738

DO - 10.1081/CNV-100107738

M3 - Article

VL - 19

SP - 779

EP - 782

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 8

ER -